Laura Joszt

Laura is the editorial director of The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®'s parent company, MJH Life Sciences®, since 2011. She has an MA in business and economic reporting from New York University.

You can reach her at ljoszt@mjhlifesciences.com or you can connect with her on LinkedIn or Twitter.


ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis

July 01, 2020

The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).

Session Highlights Barriers to Biosimilar Adoption and Lack of Provider, Payer Education

April 17, 2018

During a session at the 2018 Community Oncology Conference, hosted by the Community Oncology Alliance April 12-13 in National Harbor, Maryland, Robert M. Rifkin, MD, FACP, medical director of biosimilars at McKesson Specialty Health, The US Oncology Network, highlighted the opportunities biosimilars provide to increase access to drugs while decreasing costs, but also the remaining barriers to adoption.

New Online Consultation Tool Empowers Patients With Rheumatic Diseases, Study Finds

November 09, 2017

Chinese researchers employed a new online consultation tool to improve disease management for patients with rheumatic diseases who travel long distances for a consultation with their rheumatologist and noted significant savings for the patients.

Obese Patients With Rheumatoid Arthritis Less Likely to Achieve Remission

November 08, 2017

Research presented at the 2017 American College of Rheumatology Annual Meeting found that patients with rheumatoid arthritis and higher body mass index were less likely to achieve remission and more likely to face higher rates of disability.

Study Explores Factors That Predict RA Candidates for Successful DMARD Tapering

November 07, 2017

Researchers identify factors that make certain patients with rheumatoid arthritis good candidates for successfully tapering biologic DMARD dose.